A Comparison of Phenytoin-loading Techniques in the Emergency Department

Academic Emergency Medicine

Volumn 11, Issue 3, 2004, Pages 244-252

  Swadron, Stuart P ^a   Rudis, Maria I ^a,e   Azimian, Kian ^a,c   Beringer, Paul ^b   Fort, Diana ^a,d   Orlinsky, Michael ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c KERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adverse drug events; Anticonvulsants; Emergency department; Phenytoin; Randomized, controlled trial

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN;

ADULT; ADVERSE DRUG REACTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INFUSION; EMERGENCY WARD; EPILEPSY; FEMALE; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MALE; PAIN; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINUS TACHYCARDIA; TIME; TREATMENT OUTCOME; UNITED STATES;

EID: 1442270080     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1197/j.aem.2003.10.022     Document Type: Article

References (32)

1. Marble EL. Cost of fosphenytoin. Ann Emerg Med. 1998; 31:138-9.
2. Johnson J, Wrenn K. Inappropriate fosphenytoin use in the ED. Am J Emerg Med. 2001; 19:293-4.
3. Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology. 1978; 28(9 pt 1):874-80.
4. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA. 1983; 249:762-5.
5. Salem RB, Wilder BJ, Yost RL, Doering PL, Lee C. Rapid infusion of phenytoin sodium loading doses. Am J Hosp Pharm. 1981; 38:354-7.
6. Jung D, Powell JR, Walson P, Perrier D. Effect of dose on phenytoin absorption. Clin Pharmacol Ther. 1980; 28:479-85.
7. Wilder BJ, Serrano EE, Ramsay RE. Plasma diphenylhydantoin levels after loading and maintenance doses. Clin Pharmacol Ther. 1973; 14:797-801.
8. Van Der Meyden CH, Kruger AJ, Muller FO, Rabie W, Schall R. Acute oral loading of carbamazepine-CR and phenytoin in a double-blind randomized study of patients at risk of seizures. Epilepsia. 1994; 35(1):189-94.
9. Lund L, Alvan G, Berlin A, Alexanderson B. Pharmacokinetics of single and multiple doses of phenytoin in man. Eur J Clin Pharmacol. 1974; 7:81-6.
10. Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm. 1977; 5:579-96.
11. Evens RP, Fraser DG, Ludden TM, Sutherland EW 3rd. Phenytoin toxicity and blood levels after a large oral dose. Am J Hosp Pharm. 1980; 37:232-5.
12. Record KE, Rapp RP, Young AB, Kostenbauder HB. Oral phenytoin loading in adults: rapid achievement of therapeutic plasma levels. Ann Neurol. 1979; 5:268-70.
13. Ratanakorn D, Kaojarern S, Phuapradit P, Mokkhavesa C. Single oral loading dose of phenytoin: a pharmacokinetics study. J Neurol Sci. 1997; 147(1):89-92.
14. Osborn HH, Zisfein J, Sparano R. Single-dose oral phenytoin loading. Ann Emerg Med. 1987; 16:407-12.
15. Gerber N, Mays DC, Donn KH, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5, 5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol. 1988; 28:1023-32.
16. Marchetti A, Magar R, Fischer J, Sloan E, Fischer P. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther. 1996; 18:953-66.
17. Browne TR. Intravenous phenytoin: cheap but not necessarily a bargain. Neurology. 1998; 51:942-3.
18. DeToledo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf. 2000; 22:459-66.
19. Jamerson BD, Dukes GE, Brouwer KL, Donn KH, Messenheimer JA, Powell JR. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy. 1994; 14(1):47-52.
20. Boucher BA, Feler CA, Dean JC, et al. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy. 1996; 16:638-45.
21. Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology. 1996; 46(6 suppl 1):S17-9.
22. Coplin WM, Rhoney DH, Rebuck JA, Clements EA, Cochran MS, O'Neil BJ. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res. 2002; 24:842-8.
23. Holliday SM, Benfield P, Plosker GL. Fosphenytoin. Pharmacoeconomic implications of therapy. Pharmacoeconomics. 1998; 14:685-90.
24. Donovan PJ, Cline D. Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med. 1991; 20:139-42.
25. Meek PD, Davis SN, Collins DM, et al. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Panel on Nonemergency Use of Parenteral Phenytoin Products. Arch Intern Med. 1999; 159:2639-44.
26. Goldschlager AW, Karliner JS. Ventricular standstill after intravenous diphenylhydantoin. Am Heart J. 1967; 74:410-12.
27. DeToledo JC, Lowe MR, Rabinstein A, Villaviza N. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin [letter]. Epilepsia. 2001; 42:288.
28. Russell MA, Bousvaros G. Fatal results from diphenylhydantoin administered intravenously. JAMA. 1968; 206:2118-9.
29. Zoneraich S, Zoneraich O, Siegel J. Sudden death following intravenous sodium diphenylhydantoin. Am Heart J. 1976; 9:375-7.
30. O'Brien TJ, Cascino GD, So EL, Hanna DR. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998; 51:1034-9.
31. O'Brien TJ, Meara FM, Matthews H, Vajda FJ. Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology. 2001; 57:1508-10.
32. Collins M, Gidal BE, Garnett WR, Reinfeldt G, Tusch GM. Potential underreporting of intravenous phenytoin adverse events. Ann Pharmacother. 1999; 33(1):111-2.